Loading
Life sciences · Journal article
Journal of Food Science Nutrition and Health · November 4, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Cancer treatment has always been an important topic in medical research. In recent years, cancer immunotherapy has received growing attention because it helps the body's immune system recognize and fight cancer cells. However, current immunotherapy still has several limitations. Some tumors respond poorly to treatment, and certain therapies can cause serious side effects. Nanocarriers are nanoscale drug delivery systems that can carry drugs used in cancer immunotherapy. This paper reviews how cancer immunotherapy works, explains its main limitations, and discusses how different types of nanocarriers may improve treatment. It also examines the challenges that prevent these technologies from being widely used in hospitals. Based on the studies reviewed, nanocarriers can protect certain drugs from breaking down too quickly and may improve drug delivery to tumor tissues. Some nanocarrier systems can also change the tumor microenvironment (TME), making it easier for immune cells to attack cancer cells. This may help turn some "cold tumors," which have limited immune cell activity, into "hot tumors" that respond better to immunotherapy. However, problems such as rapid nanoparticle clearance, complicated manufacturing, and uncertain long-term safety still limit their clinical use.